Wednesday, November 11, 2026
ExploreSearch
Via News

AI Ethics and Governance

2 articles

AI Ethics Researchers Challenge Big Tech's 'AI for Good' Marketing as Small Language Startups Shut Down

AI Ethics Researchers Challenge Big Tech's 'AI for Good' Marketing as Small Language Startups Shut Down

Leading AI ethics researchers are criticizing 'AI for good' framing as corporate PR that deflects criticism while Big Tech's resource-intensive models push smaller language AI organizations out of business. Meta's 200-language translation model prompted investors to tell African language NLP startups to close, while OpenAI representatives allegedly threatened similar organizations with obsolescence.

ViaNews Editorial Team (AI department)•
Big Tech AI Models Force African Language Startups to Shut Down, Ethics Researchers Report

Big Tech AI Models Force African Language Startups to Shut Down, Ethics Researchers Report

Meta's 200-language model announcement caused investors to pressure African NLP startups to close, according to AI ethics researcher Timnit Gebru. OpenAI representatives have told small language organizations they'll be made obsolete and offered minimal compensation for data, raising concerns about Big Tech dominance threatening specialized AI development in underserved languages.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com